Main finding: Aflibercept significantly improved vision and decreased macular oedema, with greatest improvement in the first 24 weeks during fixed intravitreal Aflibercept dosing.
Purpose: To evaluate the efficacy and safety of intravitreal aflibercept injection for the treatment of macular edema secondary to central retinal vein occlusion.
Study type: Randomized controlled trial.
Condition: Central retinal vein occlusion
Participants: ≥18 yo with centre-involving macular oedema secondary to BRVO, BCVA 20/40-20/320, mean central subfield thickness ≥250 μm
n=188
Intervention:
Outcomes
Time point
AFLI + AFLI PRN/Sham
Sham + AFLI PRN
Gained ≥15 letters
Week 24
56.1%
12.3%
Week 52
55.3%
30.1%
Week 100
49.1%
23.3%
BCVA change from baseline
Week 24
+17.3
-4.0
Week 52
+16.2
+3.8
Week 100
+13.0
+1.5
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive